click below
click below
Normal Size Small Size show me how
Session 4 Pharm- 3
Pharm -3- Parkinson Disease Drugs
| Question | Answer |
|---|---|
| T/F women suffer from Parkinson's disease more than men | F |
| T/F most pts develop Parkinson's at age 40 | F most develop after age 50 |
| What is a resting tremor | palsy like movement of hands and head that disappear with purposeful movement |
| What is bradykinesia associated with Parkinson's disease | pt has difficulty initiating movement and controlling fine movements (cog wheeling, festinating, shuffling gait) |
| What are the symptoms of Parkinson's disease | resting tremors, akinesia or rigidity, bradykinesia, postural instability |
| What is the pathophysiology of Parkinson's disease | loss of dopaminergic substantia nigra neurons |
| T/F in Parkinson's disease you have an excess of Ach in the corpus striatum | T dopamine is an inhibitory signal without you get excess Ach in the corpus striatum because the cells are not inhibited properly |
| What are the common health problems in Parkinson's patients | anxiety, depression, sleep disturbances, dementia, autonomic dysfunction (urinary frequency/urgency, sexual dysfunction) |
| Is parkinsonism the same thing as Parkinson's disease | No it is just symptoms like Parkinson's disease without actual loss of substantia nigra |
| What are some common causes of parkinsonism | viral infections, head trauma, stroke, drugs that are dopamine antagonists |
| What are the 4 methods to try and restore function in Parkinson's disease | 1. neurotransmitter replacement, 2 Dopamine receptor agonist, 3 Decrease dopamine metabolism (COMT and MAO), 4 Cholinergic muscarinic antagonists |
| What are the commonly used drugs to replace dopamine | Levodopa (L-Dopa) and Carbidopa/Levodopa (Sinemet) |
| What place in Parkinson's therapy does bromocriptine play | dopamine receptor agonist |
| Name the 4 dopamine receptor agonists | bromocriptine, cabergoline, ropinirole, Pramipexole |
| What type of drug is tolcapone | COMT inhibitor decreases dopamine metabolism |
| What type of drug is Entacapone | COMT inhibitor decreases dopamine metabolism |
| What type of drug is Selegiline | MAOB inhibitor |
| What type of drug is Rasagiline | MAOB inhibitor |
| What type of drug is Trihexyphenydyl | Cholinergic muscarinic Antagonist |
| What type of drug is benzatropine | Cholinergic muscarinic Antagonist |
| What type of drug is Diphenhydramine | Cholinergic muscarinic Antagonist |
| T/F exogenous dopamine can cross the BBB | F that is why L-Dopa is administered which is a dopamine precursor |
| What is the most effective tx for motor symptoms of Parkinson's dis | Levodopa |
| Why is Levodopa combined with carbidopa | carbidopa inhibits peripheral amino acid decarboxylase making sure Levodopa doesn't get converted to dopamine before it crosses the BBB it also reduces the s/e of nausea and vomiting because it reduces dopamine in the serum |
| What adjunct can be given with levodopa to prevent the s/e of nausea and vomiting from too much dopamine in the serum | Carbidopa |
| How long does the therapeutic benefits of L-DOPA typically last | 2-5 years this is because initially the nigrostriatal neurons that remain can buffer the dopamine picking up the L-Dopa and storing and converting in with time the degeneration continues pt can't respond to L-dopa |
| What are the most common s/e of L-Dopa | N/V, Hypotension from vasodilation, cardiac arrhythmias from increase in release of nor Epi and CNS effects of dyskinesia, day time sleepiness |
| There are some behavioral s/e of taking L-Dopa what are they | hallucinations and confusion from excess dopamine in messolimbic pathway this is more common in elderly |
| What drugs can be given to address the s/e of hallucination and confusion that L-Dopa may cause | Atypical Antipsychos like clozapine and quetiapine |
| What s/e can L-Dopa have on the eye | Mydriasis and precipitatation of acute glaucoma (probably from increased nor Epi in sympathetic terminals |
| Why do you need to stop nonspecific MAOIs before giving L-Dopa | combining L-Dopa with MAOIs like phenelzine and tranylcypromine can cause life threatening hypertensive crisis and hyperpyrexia |
| What advantage does Dopamine agonists have over Dopamine replacement | does not depend on enzymatic conversion for activity (IE doesn't depend on nigrostriatal neurons to be functioning) Last longer than L-DOPA (8-12 hr half life) |
| What is the disadvantage with Dopamine Receptor agonists | Increased rate of hallucinations and hypotension as compared to L-DOPA |
| What are the first generation dopamine receptor agonists | Bromocriptine (Parlodel) |
| What is the 2nd gen dopamine receptor agonist | Cabergoline (selective for D2 receptor) |
| What is the non ergot selective D2 receptor agonist meds | Ropirinole(Requip), Pramipexole Mirapex), and Apomorphine |
| Why do you want to start bromocriptine at low doses to start tx | can cause profound hypotension |
| What s/e does bromocriptine have | Hypotension, Nausea and Fatigue (usually transient) |
| What advantage do the non ergot D2 receptor agonist have over ergot derived | Initiate more quickly reach therapeutic doses in a week or less but cause hallucinations and somnolence |
| What do you need to be aware of when dosing Pramipexole in pts since it is excreted unchanged | if they have kidney disease you need to adjust the dose |
| Why are the dopamine receptor agonist taking over as first line tx for Parkinson disease over L-DOPA | they show less incidence of on/off effects and less degeneration of dopaminergic neurons |
| What is the MOA of COMT inhibitors | block peripheral conversion of L-Dopa to methyl dopa increasing L-Dopa that reaches CNS, |
| Which of the COMTS Tolcapone (Tasmar) or Entacapone (COMTAN) also inhibits COMT in the CNS as well as periphery | Tolcapone (Tasmar) |
| What are the s/e of Tolcapone (Tasmar) | Nausea, Orthostatic hypotension, confusion and hallucinations. Hepatotoxicity in 2% of pts monitor this |
| Which drug Tolcapone (Tasmar) or Entacapone (Comtan) both COMT inhibitors has a longer duration of action | Tolcapone the half-life of entacapone is only 2hrs |
| Does Entacapone (Comtan) require hepatic monitoring | No it is not hepatotoxic like Tolcapone |
| Why would you give MAO-B inhibitor Selegiline (Eldepryl) over the non selective MAO inhibitors if they both fulfill the same role in inhibiting peripheral metabolism of Levodopa | does not cause hypertensive crisis like the nonselective MAOIs |
| Your pt is no longer responding to Levodopa and is in advanced Parkinson disease would it be beneficial to add selegiline to their tx why or why not | No- it increases the adverse motor and cognitive effects of L-DOPA therapy in later or advanced Parkinson disease. It should be used in early tx of disease where it is actually neuroprotective |
| Why would you use Muscarinic Antagonists in Parkinson Disease tx | useful as an adjunct to treat parkinsonian activity |
| What are the s/e of using the Muscarinic Antagonists | Sedation and Mental Confusion, Blurred vision (cycloplegia) use caution in pts with narrow angle glaucoma, Constipation and urinary retention |
| What was Amantadine (Symmetrel) originally made for | prophylaxis and tx of influenza as an antiviral |
| What is the MOA of amantadine (Symmetrel) in Parkinson disease | blocks NMDA glutamate receptors to block excitotoxicity (remember dopamine is typically and inhibitory signal this would mimic that) It also alters dopamine release in the striatum and has anticholinergic properties |
| T/F Amantadine is very effective in tx all stages of Parkinson disease | F- effects are modest used as initial therapy for mild PD |
| What are the s/e of Amantadine | Dizziness, Lethargy, Sleep Disturbances, Anticholinergic Effects, N/V (Mild and reversible) |